Table 2.
HSCT-related variables for study population (N = 127)
| Characteristic | IC without VEN (N = 44) | LIT without VEN (N = 29) | LIT with VEN (N = 54) | P value∗ |
|---|---|---|---|---|
| Best hematologic response before HSCT | ||||
| CR | 37 (84) | 24 (83) | 42 (78) | .44 |
| CRi | 7 (16) | 3 (10) | 8 (15) | |
| MLFS | 0 | 2 (7) | 4 (7) | |
| MRD status before HSCT | ||||
| MRD– | 23 (52) | 11 (38) | 28 (52) | .03 |
| MRD+ | 17 (39) | 17 (59) | 11 (20) | |
| Insufficient/not done | 4 (9) | 1 (3) | 15 (28) | |
| Number of cycles before HSCT | 3 (1-6) | 4 (1-12) | 3 (1-12) | .01 |
| Months from diagnosis to HSCT | 5.0 (2.0-13.5) | 5.0 (2.8-16.5) | 4.2 (2.1-17.0) | .03 |
| Transplant conditioning intensity† | ||||
| MAC | 28 (64) | 18 (62) | 20 (37) | .01 |
| RIC | 15 (34) | 11 (38) | 34 (63) | |
| Unknown | 1 (2) | 0 | 0 | |
| GVHD prophylaxis | ||||
| MTX + tacrolimus ± MMF | 25 (57) | 22 (76) | 8 (15) | <.0001 |
| Cyclophosphamide + tacrolimus ±MMF | 16 (36) | 7 (24) | 45 (83) | |
| Other | 2 (5) | 0 | 0 | |
| Unknown | 1 (2) | 0 | 1 (2) | |
| HCT-CI score | ||||
| 0 | 5 (11) | 5 (17) | 10 (19) | .27 |
| 1-2 | 13 (30) | 9 (31) | 24 (44) | |
| ≥3 | 26 (59) | 15 (52) | 20 (37) | |
| HLA matching | ||||
| Matched unrelated donor | 22 (50) | 20 (69) | 29 (54) | .45 |
| Matched related donor | 15 (34) | 8 (28) | 16 (30) | |
| Haploidentical donor | 6 (14) | 1 (3) | 8 (15) | |
| Unknown | 1 (2) | 0 | 1 (2) | |
| Received post HSCT maintenance | 4 (9) | 7 (24) | 8 (15) | .37 |
| HMA alone | 3 (7) | 5 (17) | 5 (9) | |
| HMA plus venetoclax | 0 | 2 (7) | 1 (2) | |
| FLT3 inhibitor | 1 (2) | 0 | 2 (4) | |
| None | 40 (91) | 22 (76) | 46 (85) |
Continuous variables are listed as median (range) and categorical variables as N (%) or n/N (%).
CRi, complete remission with incomplete count recovery; MAC, myeloablative conditioning; MLFS, morphologic leukemia-free state; MMF, mycophenolate mofetil; MTX, methotrexate; RIC, reduced-intensity conditioning; VEN, venetoclax.
Two patients with a haploidentical donor also received 5 mg/kg of thiotepa.
RIC: Fludarabine ranging from 25 to 30 mg/m2 with melphalan 100 mg/m2 or 140 mg/m2.27 Thirteen patients with haploidentical donors also received 200 cGy of total body irradiation.
P value is for comparison of groups with available data only (excluding those with unknown values).
MAC: Fludarabine 40 mg/m2 with pharmacokinetic-guided busulfan dose to reach target total course area under the curve from 16 000 to 24 000 μmol/min.28